Selegiline
Emsam, Selegiline, Zelapar (selegiline) is a small molecule pharmaceutical. Selegiline was first approved as Selegiline hydrochloride on 1989-06-05. It is used to treat alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, and schizophrenia in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target amine oxidase [flavin-containing] A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Emsam, Zelapar (generic drugs available since 1997-04-01, discontinued: Eldepryl)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selegiline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMSAM | Somerset Pharma | N-021336 RX | 2006-02-27 | 3 products, RLD |
Selegiline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZELAPAR | Bausch Health Companies | N-021479 RX | 2006-06-14 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| emsam | New Drug Application | 2020-05-15 |
| selegiline hydrochloride | ANDA | 2024-10-01 |
| zelapar | New Drug Application | 2021-06-01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 5 | 1 | 6 |
| Healthy volunteers/patients | — | — | — | — | — | — | 2 | 1 | 3 |
| Depression | D003863 | — | F33.9 | — | — | 1 | 2 | — | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 1 | 2 | — | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | 1 | 1 | 3 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | 1 | — | 1 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | — | — | 1 | — | 1 |
| Sleepiness | D000077260 | — | R40.0 | — | — | — | 1 | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | — | 1 |
| Tissue adhesions | D000267 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | 4 | 1 | — | — | 6 |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | 1 | — | — | 1 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | — | 1 | 3 |
| Cognition disorders | D003072 | — | — | — | 2 | — | — | 1 | 3 |
| Tobacco use disorder | D014029 | — | F17 | — | 2 | — | — | 1 | 3 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | 1 | 2 |
| Neurocognitive disorders | D019965 | — | F09 | — | 1 | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
| Tobacco use cessation | D020340 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
| Meniere disease | D008575 | EFO_0006862 | H81.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Selegiline |
| INN | selegiline |
| Description | (-)-selegiline is a selegiline and a terminal acetylenic compound. It has a role as a geroprotector. It is a conjugate base of a (-)-selegiline(1+). |
| Classification | Small molecule |
| Drug class | Monoamine oxidase (MAO) inhibitors, type B |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#CCN(C)[C@H](C)Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 14611-51-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL972 |
| ChEBI ID | 9086 |
| PubChem CID | 26757 |
| DrugBank | DB01037 |
| UNII ID | 2K1V7GP655 (ChemIDplus, GSRS) |
Target
Agency Approved
MAOB
MAOB
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Selegiline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,102 documents
View more details
Safety
Black-box Warning
Black-box warning for: Emsam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,217 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use